Use of Botulinum Toxin to Treat Psoriasis

Sponsored by University of Minnesota - Clinical and Translational Science Institute

Phase Quota
Phase 1

Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.

Study Start Date: January 2009

Estimated Completion Date: December 2015

Specialties: Dermatology: Clinical Pharmacology,Psoriasis Internal Medicine: Clinical Pharmacology,Dermatology Pharmacy: Drug Trials


  • Biological: injection of botulinum toxin type A.
  • Procedure: normal saline
  • Procedure: injection of botulinum toxin type A.

Inclusion criteria

  • Healthy subjects. Psoriasis vulgaris diagnosis made by a board certified dermatologist involving at least one area that has been intolerant or recalcitrant to at least two forms of recognized topical or systemic treatments in the past. In addition, the subject should have at least a score of 2 for keratoderma and erythema. Signed informed consent. Willing to adhere to protocol

Exclusion criteria

  • Immunosuppressed patients, pregnant, secondary skin infections, phototherapy within 4 weeks of the botulinum toxin injection, exposure to any topical or systemic retinoid treatment with the last 12 months, volunteers taking chloroquine and hydroxychloroquine, volunteers on warfarin

Study Locations And Contact Information

  • Univerisity of Minnesota, Minneapolis Minnesota

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.